Dopamine News and Research

Latest Dopamine News and Research

New stem cell technique hopes to replace damaged cells in Parkinson's

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson's disease. The technique could be developed for application in other degenerative conditions.

13 Nov 2011

Parkinson’s disease breakthrough using stem cell therapy

Australian scientists are on the brink of a discovery that could change treatment of patients with Parkinson’s disease (PD). Transplanting stem cells could be the next big thing in PD therapy they claim.

13 Nov 2011

Worm model to evaluate drugs for Parkinson's disease

Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson's disease.

11 Nov 2011

Patients with Parkinson's may have increased risk of leg motor restlessness

People with Parkinson's disease may be more likely to have a movement disorder called leg motor restlessness, but not true restless legs syndrome as previous studies have suggested, according to a study published in the November 9, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

10 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

Stem cell therapy for Parkinson’s

U.S. researchers have finally found a way to overcome difficulties in coaxing human embryonic stem cells to become the neurons killed by Parkinson's disease.

8 Nov 2011

Link between heavy methamphetamine use and schizophrenia

In the first worldwide study of its kind, scientists from Toronto's Centre for Addiction and Mental Health (CAMH) found evidence that heavy methamphetamine users might have a higher risk of developing schizophrenia.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Toxoplasma gondii directly affects production of dopamine in brain

A research group from the University of Leeds has shown that infection by the brain parasite Toxoplasma gondii, found in 10-20 per cent of the UK's population, directly affects the production of dopamine, a key chemical messenger in the brain.

5 Nov 2011

Amphetamine use in adolescence can affect brain chemistry and behaviour

Amphetamine use in adolescence can cause neurobiological imbalances and increase risk-taking behaviour, and these effects can persist into adulthood, even when subjects are drug free. These are the conclusions of a new study using animal models conducted by McGill University Health Centre (MUHC) researcher Dr. Gabriella Gobbi and her colleagues.

4 Nov 2011

Restoration of dopamine levels could potentially prevent drug abuse

Portuguese researchers have discovered that rats exposed before birth to glucocorticoids not only show several brain abnormalities similar to those found in addicts, but become themselves susceptible to addiction (the glucorticoids, which are stress hormones, were used to mimic pre-natal stress).

1 Nov 2011

Oscillatory signals in basal ganglia cause motor deficits in Parkinson's

The research group headed by Professor Atsushi Nambu and Professor Masahiko Takada has shown that the 'oscillatory' nature of electrical signals in subcortical nuclei, the basal ganglia, causes severe motor deficits in Parkinson's disease, by disturbing the information flow of motor commands.

1 Nov 2011

First rapid measurements of dopamine release in human brain

A research team led by investigators at the Virginia Tech Carilion Research Institute has demonstrated the first rapid measurements of dopamine release in a human brain and provided preliminary evidence that the neurotransmitter can be tracked in its movement between brain cells while a subject expresses decision-making behavior.

29 Oct 2011

No link between Chantix and mental health problems says FDA

According to federal health officials this Monday Pfizer's anti-smoking drug Chantix – known as Varenicline, did not increase psychiatric problems like depression and suicidal thoughts in two studies, though the findings are not definitive.

25 Oct 2011

BPA exposure in mothers may affect unborn daughters’ behavior: Study

A new federal study revealed Monday in the journal Pediatrics shows that bisphenol A (BPA) - a chemical used widely in plastic bottles, metal cans and other consumer products could be linked to behavioral and emotional problems in toddler girls.

25 Oct 2011

Specific dopamine system gene variants linked to ADHD medication response in children

Children with certain dopamine system gene variants have an improved response to methylphenidate - the most commonly prescribed medication for Attention Deficit Hyperactivity Disorder - in a finding that could help eliminate the guesswork from prescribing effective medications for children with ADHD.

22 Oct 2011

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

Brain scans can evaluate new treatments for attention deficit disorder

Scientists have developed a way to evaluate new treatments for some forms of attention deficit disorder. Working in mice, researchers at Washington University School of Medicine in St. Louis showed that they can use brain scans to quickly test whether drugs increase levels of a brain chemical known as dopamine.

15 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

DaTscan aids doctors in diagnosing patients with Parkinson's disease

Fifty thousand to 60,000 new cases of Parkinson's disease are diagnosed in the United States each year. Central DuPage Hospital (CDH) in Winfield, Ill., is among the first medical centers in North America to be using a new technology called DaTscan, an imaging tool that aids doctors in diagnosing patients who demonstrate Parkinsonian symptoms, like Parkinson's disease.

29 Sep 2011